抗 CD20 治疗后 B 细胞淋巴细胞严重耗竭的血液病患者合并 SARS-CoV-2 肺炎的恢复期血浆治疗：单中心经验及文献综述

Convalescent plasma (CP) therapy might be effective in patients with haematological malignanciesand B-cell depletion.

We report a single-centre experience of COVID-19 patients with non-Hodgkinlymphoma and absence of B-cells as a consequence of anti-CD20 therapy successfully treated withCP from October 2020 to May 2021. CP was given in the presence of pneumonia with respiratoryfailure despite standard treatment and consisted of three infusions on an alternate-day basis.

A reviewof the current literature on this topic was also performed. Six patients were identified (medianage 59. 5 years (range 50-73)). The last anti-CD20 drug administration occurred 60 days before infection(range 0-360). CP was administered after a median of 51 days (range 9-120) from SARS-CoV-2diagnosis, with an early improvement in all but one subject.

We suggest a possible clinical benefitof convalescent CP treatment in COVID-19 patients with haematological malignancies and B-celldepletion having persistent/recurrent pneumonia.